Showing results (1-10 of 299) with videos related to
Sort By:
Pageof 30
Expert Opinion on Biological Therapy|December 4, 2012
Aflibercept in lung cancerJoel W Neal, Heather A WakeleeClinical Lung Cancer|February 11, 2015
Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung CancerYing Liang, Heather A Wakelee, Joel W NealTranslational Lung Cancer Research|March 26, 2015
MET inhibitors in combination with other therapies in non-small cell lung cancerSukhmani Padda, Joel W Neal, Heather A WakeleeClinics in Chest Medicine|November 8, 2011
Current management of small cell lung cancerJoel W Neal, Matthew A Gubens, Heather A WakeleeJournal of the National Comprehensive Cancer Network : JNCCN|April 16, 2013
A patient with anaplastic lymphoma kinase-positive non-small cell lung cancer with development of leptomeningeal carcinomatosis while on targeted treatment with crizotinibJonathan W Riess, Seema Nagpal, Joel W Neal, et al.Clinical Lung Cancer|November 10, 2020
Opportunistic Invasive Fungal Infections Mimicking Progression of Non-Small-Cell Lung CancerMarian Park, Dora Y Ho, Heather A Wakelee, et al.Lung Cancer (Amsterdam, Netherlands)|August 16, 2015
Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospectsJody C Chuang, Joel W Neal, Xiao-Min Niu, et al.Cancer Treatment and Research Communications|December 17, 2021
Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung CancerJacqueline V Aredo, Heather A Wakelee, Joel W Neal, et al.Clinical Therapeutics|July 3, 2016
Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted TherapyJody C Chuang, Joseph B Shrager, Heather A Wakelee, et al.Clinical Lung Cancer|July 10, 2024
Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung CancerArpeet T Shah, Isabelle Blanchard, Sukhmani K Padda, et al.Pageof 30